#152110

T47D/TR-2 Cell Line

Cat. #152110

T47D/TR-2 Cell Line

Cat. #: 152110

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-5 days

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Tumour line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne Lykkesfeldt

Institute: Danish Cancer Society, Denmark

Primary Citation: Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: T47D/TR-2 Cell Line
  • Cancer: Breast cancer
  • Cancers detailed: Breast carcinoma;Tamoxifen resistant
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: T47D/S2
  • Organism: Human
  • Gender: Female
  • Tissue: Breast
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Description: The T47D-182R-1 cell line is an adherent breast cancer cell line resistant to fulvestrant (Faslodex). It is derived from the human breast cancer cell line - T47D/S5 by long term treatment with 100 nM fulvestrant. T47D-182R-1 is adherent and the morphology is epithelial. Resistance will inevitably occur for the second-line therapy fulvestrant. Therefore, this is a highly valuable tool in extending knowledge of acquired therapeutic resistance to ultimately find targeted treatments to resistant tumour cells. As well as treament that can inhibit or delay the emergence of resistance.
  • Application: Determining molecular mechanisms around tamoxifen resistance
  • Production details: The T47D/TR-2 cell line has been established by long term treatment of T47D/S2 cells with 1 uM tamoxifen. Clonal selection was performed in medium without tamoxifen. After growth in presence of 1 uM tamoxifen for 10 months, the growth rate was similar to the parental cells.
  • Biosafety level: 1
  • Cellosaurus id: CVCL_1D37

Target Details

  • Target: Oestrogen receptor

Applications

  • Application: Determining molecular mechanisms around tamoxifen resistance
  • Application notes: The T47D/TR-2 cell line is a breast cancer cell line resistant to tamoxifen. This cell line has been established from T47D/S2 cells. T47D/TR-2 is adherent and the morphology is polygonal epithelial. T47D/TR-2 cells oestrogen receptor (alpha) positive and express progesterone receptor, although at a reduced level compared to parental T7D/S2 cells. Antioestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. This cell line allows the study of the mechanisms involved in tamoxifen resistant breast cancer cell growth.

Handling

  • Format: Frozen
  • Passage number: Passage 164 (AL3575, AL3576)
  • Growth medium: Phenol red free RPMI 1640 + 2% FCS + glutamax + 8ug Insulin/ml + 1 uM tamoxifen T47D/TR-2 are growth inhibited by fulvestrant.
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

Related Tools

  • Related tools: T47D/S2 Cell Line

References

  • Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
  • Larsen et al. 2015. BMC Cancer. 15(1):1-15. PMID: 25885472.
  • Thrane et al. 2014. Oncogene. 34(32): 4199-4210. PMID: 25362855.
  • Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.